Novartis Venture Fund: BioVenture Fund

Five Cambridge Center

Cambridge, MA 02142

617 871 7788

www.venturefund.novartis.com

Abstract Description

Venture fund focused on health sciences.

Management

Dr. Campbell Murray. Managing Director Dr. Lauren Silverman. Managing Director Dr. Henry Skinner. Managing Director Steven D. Weinstein. Managing Director

Keywords

health science, capital, business

Comment | Printable Version | 1 of 1 | |

network/Financial and Investment/Venture Fund

Description

The Novartis Venture Fund has venture capital of CHF 150 million and USD 100 million. The Fund supports new business projects that show exemplary entrepreneurial and innovative spirit in future-oriented areas, especially in the field of Health Sciences.

Relevant Relationships

Aileron Therapeutics Inc. Akebia Therapeutics, Inc. Alios BioPharma, Inc. Anchor Therapeutics Inc. Avila Therapeutics, Inc. Bicycle Therapeutics Ltd. BioRelix Inc. Catalyst Biosciences Inc. Cellerix SA Covagen AG Cylene Pharmaceuticals Inc. Destiny Pharma Ltd. Diagnoplex Biosciences AG Euthymics Bioscience, Inc. Eyesense AG Forma Therapeutics Inc. Genedata AG GlycoMimetics Inc. Heptares Therapeutics Ltd. Immune Targeting Systems Ltd. Intellikine, Inc LigoCyte Pharmaceuticals, Inc. MerLion Pharmaceuticals Pte Ltd. Merus Biopharmaceuticals BV MicroCHIPS Inc. Nabriva Therapeutics AG NanoPowers AG Neomics Co. Ltd Nereus Pharmaceuticals Inc. NovImmune AG Okairos AG Opsona Ltd Oxagen Ltd. Paratek Pharmaceuticals Inc. PharmAbcine Polyphor AG Portaero, Inc. ProCertus BioPharm, Inc. Proteostasis Therapeutics Inc. PTC Therapeutics Inc Pulmatrix, Inc. Quro Science Inc. Ra Pharmaceuticals, Inc. S*BIO Pte Ltd Sonitus Medical Inc Symetis AG Tepha Inc. Tokai Pharmaceuticals Trellis Bioscience, Inc. Viamet Pharmaceuticals, Inc.

2012-02-08-2188 SELECT * FROM `master` WHERE CompanyID='2910' AND `Profile_Type` LIKE 'resource' AND `Approved` LIKE 'YES' ORDER BY `Member_Priority` ASC LIMIT 0 , 30